Page 40 - Read Online

Page 10 of 11 Shah et al. Vessel Plus 2021;5:53 https://dx.doi.org/10.20517/2574-1209.2021.76

significant advances on the horizon.

DECLARATIONS
Authors’ contributions
Contributed to the writing of this review paper: Shah RJ, Pan S, Lanier GM, Mellela L, Aronow WS, Jain D

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflict of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Koike H, Katsuno M. Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies.
Neurol Ther 2020;9:317-33. DOI PubMed PMC
2. Giorgetti A, Genovesi D, Milan E, et al; Italian Group of Nuclear Cardiology (GICN). Cardiac amyloidosis. Clin Transl Imaging
2019;7:21-32. DOI
3. Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transythretin amyloidosis.
Circulation 2019;140:16-26. DOI PubMed
4. Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic
variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008;40:232-9. DOI PubMed
5. Coelho T, Maurer MS, Suhr OB. THAOS - The transythretin amyloidosis outcome survey: initial report on clinical manifestations in
patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013;29:63-76. DOI
6. Jacobson DR, Alexander AA, Tagoe C, et al. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-
Americans. Amyloid 2015;22:171-4. DOI PubMed
7. Kittleson MM, Maurer MS, Ambardekar AA, et al. American Heart Association Heart Failure and Transplantation Committee of the
Council on Clinical Cardiology. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the american
heart association. Circulation 2020;142:e7-22. DOI PubMed
8. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.
DOI PubMed
9. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art review. J Am
Coll Cardiol 2019;73:2872-91. DOI PubMed PMC
10. Castaño A, Maurer MS. Cardiac amyloidosis. Heart failure: a companion to Braunwald's heart disease. 4th ed. Elsevier; 2020. p. 301-
10.e3. DOI
11. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med
2018;28:10-21. DOI PubMed PMC
12. Suhr OB, Coelho T, Buades J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose
study. Orphanet J Rare Dis 2015;10:109. DOI PubMed PMC
13. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J
Med 2018;379:11-21. DOI PubMed
14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with
hereditary transthyretin-mediated amyloidosis. Circulation 2019;139:431-43. DOI PubMed
15. Judge DP, Kristen AV, Grogan M, et al. Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated